| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ipsen S.A (PA: IPN)
IPN Technical Analysis
5
| As on 27th Feb 2026 IPN STOCK Price closed @ 165.10 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 109.92 & Strong Buy for SHORT-TERM with Stoploss of 115.08 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IPNSTOCK Price
| Open | 160.80 | Change | Price | % |
| High | 165.10 | 1 Day | 4.60 | 2.87 |
| Low | 160.70 | 1 Week | 7.80 | 4.96 |
| Close | 165.10 | 1 Month | 30.60 | 22.75 |
| Volume | 282586 | 1 Year | 55.60 | 50.78 |
| 52 Week High 165.10 | 52 Week Low 90.70 | ||||
PA France Most Active Stocks
| FTI | 5.91 | -1.66% |
| VIEDS | 0.72 | 4.35% |
| EDEN | 19.60 | 0.05% |
| ALNEV | 0.00 | % |
| BOL | 4.96 | -0.20% |
| DSY | 18.55 | 0.87% |
| CS | 41.46 | 1.47% |
| ALNRG | 0.01 | 0.00% |
| ORA | 18.19 | 1.96% |
| ALEUP | 0.04 | 33.33% |
PA France Top Gainers Stocks
PA France Top Losers Stocks
| IPN Daily Charts |
IPN Intraday Charts |
Whats New @ Bazaartrend |
IPN Free Analysis |
|
|
IPN Important Levels Intraday
| RESISTANCE | 173.58 |
| RESISTANCE | 170.86 |
| RESISTANCE | 169.18 |
| RESISTANCE | 167.50 |
| SUPPORT | 162.70 |
| SUPPORT | 161.02 |
| SUPPORT | 159.34 |
| SUPPORT | 156.62 |
IPN Forecast March 2026
| 4th UP Forecast | 197.28 |
| 3rd UP Forecast | 186.96 |
| 2nd UP Forecast | 180.58 |
| 1st UP Forecast | 174.2 |
| 1st DOWN Forecast | 156 |
| 2nd DOWN Forecast | 149.62 |
| 3rd DOWN Forecast | 143.24 |
| 4th DOWN Forecast | 132.92 |
IPN Weekly Forecast
| 4th UP Forecast | 176.08 |
| 3rd UP Forecast | 172.56 |
| 2nd UP Forecast | 170.38 |
| 1st UP Forecast | 168.21 |
| 1st DOWN Forecast | 161.99 |
| 2nd DOWN Forecast | 159.82 |
| 3rd DOWN Forecast | 157.64 |
| 4th DOWN Forecast | 154.12 |
IPN Forecast2026
| 4th UP Forecast | 313.77 |
| 3rd UP Forecast | 266.09 |
| 2nd UP Forecast | 236.62 |
| 1st UP Forecast | 207.15 |
| 1st DOWN Forecast | 123.05 |
| 2nd DOWN Forecast | 93.58 |
| 3rd DOWN Forecast | 64.11 |
| 4th DOWN Forecast | 16.43 |
Ipsen S.A ( PA France Symbol : IPN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IPN Business Profile
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA. Address: 65, quai Georges Gorse, Boulogne-Billancourt, France, 92650
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service